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A B S T R A C T
Tissue engineered blood vessels (TEBVs) hold great promise for clinical use in patients with end stage renal
disease (ESRD) requiring vascular access for hemodialysis. A promising way to make TEBVs is to exploit foreign
body response (FBR) of polymeric rods used as templates. However, since the FBR predominantly involves bone-
marrow (BM) derived cells and ESRD coincides with impaired function of BM, it is important to assess the
generation of TEBVs in conditions of renal failure. To this end, we implanted polymer rods in the subcutis of rats
after BM-transplantation with GFP-labeled BM cells in a model of chronic kidney disease (CKD). At 3 weeks after
implantation, rods were encapsulated by tissue capsule (TC) composed of collagen, myofibroblasts and mac-
rophages. On average, 13% of CD68+ macrophages were GFP+, indicating BM origin. Macrophage-to-myofi-
broblasts differentiation appeared to play an important role in TC formation as 26% of SMA+/GFP+ myofi-
broblasts co-expressed the macrophage marker CD68. Three weeks after rod implantation, the cellular response
changed towards tissue repair, characterized by 40% increase in CD68+/CD163+ repair associated macrophages
and 95% increase in TGFβ and IL10 gene expression as compared to TCs harvested at 1 week. These results show
that both BM derived and tissue resident cells, contribute to TC formation, whereas macrophages serve as
precursors of myofibroblasts in mature TCs. Finally, the presence of CKD did not significantly alter the process of
TC formation, which holds the potential to support our approach for future clinical use in ESRD patients.
1. Introduction
Patients with cardiovascular disease (CVD) or end-stage renal dis-
ease (ESRD) frequently require surgery to either replace diseased blood
vessels or create a vascular access site for hemodialysis [1–3]. For this
purpose, native veins are generally preferred due to superior patency
rates when compared to prosthetic grafts, but often unavailable due to
preexisting vascular pathology [4,5]. The failure of synthetic vascular
grafts predominantly results from the development of intimal hyper-
plasia ultimately leading to graft occlusion, and a relatively high risk of
infectious complications [6–8]. In recent years, various strategies to
create tissue engineered vascular grafts have been developed in an
effort to overcome current limitations of synthetic grafts and diseased
native blood vessels [9–11]. Indeed, tissue engineered blood vessels
(TEBVs) can be tailor-made, do not have inconvenient valves and side-
branches, are free from pre-existing vascular diseases and have the
potential to adapt to changing hemodynamic conditions.
Our approach to generate autologous TEBVs in vivo is based on the
foreign body response (FBR) directed to a subcutaneously implanted
polymer rod that culminates in the formation of a fibrocellular tissue
capsule (TC), that encapsulating the rod [12]. Upon extraction of the
polymer rod several weeks after implantation, the remaining TC is
grafted into the vasculature, whereupon it differentiates into a blood
vessel. In this approach, the subcutaneous space is utilized as an in situ
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bioreactor to grow a completely autologous blood vessel. In a previous
study in pigs, we demonstrated that upon vascular grafting, the TCs
phenotypically differentiate towards a blood vessel, as demonstrated by
enhanced matrix synthesis, differentiation of fibroblasts toward con-
tractile vascular smooth muscle cells (VSMCs) and endothelialization of
the luminal surface [13].
The dynamics of the FBR to implanted materials have been eluci-
dated in detail [14]. The early phase of the FBR is characterized by the
recruitment of inflammatory cells, which is followed by the formation
of granulation tissue, ultimately resulting in a fibrocellular TC, which
completely encapsulates the implanted foreign body [15]. However, the
origin of the cells present within the TCs is still unknown. Under-
standing the origin of cells present in the TC is of vital importance for
its application as vascular grafts, as various disease conditions such as
diabetes mellitus, chronic kidney disease (CKD) and ischemic periph-
eral arterial disease coincide with impaired function of bone marrow
(BM)-derived cells [16–18], which could hamper TC formation.
In the present study, we aimed to elucidate the contribution of BM-
derived cells in TC formation in a rat model of green fluorescent protein
(GFP) BM transplantation [19]. Furthermore, we combined this model
with a model of CKD to investigate its effect on TC composition.
2. Material and method
2.1. Study design
All the animal work was performed at the University of California,
Los Angeles and approved by the institutional animal care and use
committee. Five-weeks old male Sprague Dawley (SD) rats (200–250 g)
were purchased from Jackson Laboratory (USA) (n= 27), transgenic
enhanced GFP SD rats (SD-Tg (UBC-EGFP)2BalRrrc) were purchased
from rat resource and resource center (University of Missouri,
Columbia, USA) (n=9). All animals were housed in the local facilities
accredited by the American Association for Accreditation of Laboratory
Animal Care and were maintained under controlled conditions of light,
temperature, and humidity.
2.2. Bone marrow transplantation
After 1-week acclimatization to the new environment, SD-Tg (UBC-
EGFP)2BalRrrc rats were used as donor rats for the extraction of bone
marrow cells (BMCs). BMCs were harvested from the femurs and tibias
of 6 to 8-weeks-old SD-Tg (UBC-EGFP)2BalRrrc rats and the nucleated
cells were enriched by lysing red blood cells with Red blood cell lysis
buffer (1.2 mL, Sigma, St Louis, MO, USA). The recipient SD rats were
lethally irradiated with two apart doses of 5,5Gy each (11Gy in total)
with a 4 h brake using a cobalt-60 gamma source. BMCs (2*107) were
injected via tail vein into recipient rats 24 h after irradiation. To pre-
vent infections after BM transplantation antibiotic sulfamethoxazole
and trimethoprim (0.5 mg/kg) was administrated via the drinking
water for 12 days post transplantation. Three weeks after BM recon-
stitution peripheral blood (0.2 mL) was collected from the tail vein to
determine enrichment in GFP+ cells by fluorescence-activated cell
sorting (FACS) analysis.
2.3. Model of chronic kidney disease
All operations were performed under isoflurane anesthesia. Three
weeks after BM transplantation rats were randomly divided into two
experimental groups: healthy controls (n= 10) and rats with CKD
(n=17). CKD was induced by two-stage subtotal nephrectomy (unin-
ephrectomy of left kidney (UNX) followed 7 days later by 2/3 removal
of right kidney), as described previously [20,21]. Two weeks later CKD
was confirmed by measuring serum creatinine and blood urea nitrogen
(BUN).
2.4. Implant material
Solid cylindrical-shaped rods composed of the elastomeric co-
polymer PEOT/PBT of 1.75–0.25mm in diameter and 1.5 cm in length
were fabricated with a rapid prototyping unit33 (Envisiontec GmbH,
Gladbeck, Germany) used as melt extruder. Rods were composed of the
co-polymer poly (ethylene oxide terephthalate)epoly (butylene ter-
ephthalate) (PEOT/PBT, Polyvation, The Netherlands), with a PEOT/
PBT weight percentage of 55/45 and 300 g/mol molecular weight of
the initial polyethylene glycol used for the copolymer reaction. The
implant surface was modified by etching with chloroform as previously
described [12,22]. Surface topography of all modified rods was eval-
uated using scanning electron microscopy (SEM). Rods were sterilized
by gamma irradiation at a minimum dose of 25 kGy (Synergy Health
Ede, the Netherlands). The effect of gamma-radiation on the surface
was evaluated using SEM.
2.5. Implantation of polymeric rods
Per rat, four rods were implanted in the subcutaneous space of the
abdominal area. First pair of rods were inserted at 2 weeks after CKD
induction and 5 weeks after BM transplantation, and left in place for 3
weeks. One week before rods extrusion another pair of rods were in-
serted for 1-week time point. Following a small horizontal incision of
ca. 0.5 cm, a longitudinal subcutaneous pocket was formed where the
rods were inserted. The incision was closed using 4–0 vicryl sutures
(Johnson & Johnson, NJ, USA). The skin was closed intracutaneously.
Rats directly received post operational analgesia via pre-operative in-
jection of buprenorphine (0.01–0.05mg/kg) and 2oz gel cups with
Carprofen (5mg/kg) were placed into the cages for up to 3 days post-
surgery. One or three weeks after insertion of the rods, tissue capsules
were harvested and animals were euthanized by CO2 asphyxiation. In
short, a longitudinal incision lateral to the rod was made and the tissue
capsule was gently removed from the surrounding tissue. After har-
vesting, rods could easily be extruded from the tissue capsule.
2.6. Morphometric and histological analysis
Tissue capsules containing rods were fixed in 4% paraformaldehyde.
After extrusion of the rods, tissue capsules were processed and em-
bedded in paraffin. Serial cross sections of 5mm of two parts of each
tissue capsule were made for immunohistochemical and immuno-
fluorescence analysis. To characterize the extracellular matrix, serial
sections of each tissue capsule were stained with picrosirius red for
collagen and Movat's stain for other extracellular matrix (ECM) com-
ponents. Total collagen content was analyzed using QuickZyme Total
Collagen Assay Kit (Biosciences, the Netherlands) according to the
manufacturer protocol. In brief, five to ten 10 μm tissue sections were
hydrolyzed by o/n incubation at 95 °C in a heat block. Upon hydrolysis,
35 μl was used for collagen quantification. The assay measured the
total amount of hydroxyproline present in the sample after 90min of
incubation time, which represents all collagen-types present in the
sample. The assay results in a chromogen with an absorbance maximum
at 570 nm.
Cellular composition of tissue capsules was characterized using
immunohistochemistry, with antibodies against a-smooth muscle actin
(1:1000; Dako M0851, CA, USA) for myofibroblasts, CD68 (1:300;
Abcam Ab31630, Cambridge, UK) for macrophages and Ki67 (1:100;
BD-Pharmigen 550609, CA, USA) for proliferating cells and visualized
with 3,3¢-diaminobenzadine (DAB).
To visualize GFP+ cells sections were stained with anti-GFP anti-
body (1:100; Abcam, ab13970, Cambridge, UK) with secondary Cy5
conjugated Goat anti-Chk IgY (1:500; Abcam ab97147, Cambridge,
UK). For immunofluorescent staining of CD68 after primary antibody
Alexa 568 conjugated goat anti mouse IgG1 (1:300; Molecular Probes
A21124, OR, USA) was used. SMA was counterstained with Alexa 488
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conjugated secondary mouse IgG2a (1:250; Molecular Probes A21131,
OR, USA). Stem/progenitor cell-like population was stained with
CD133 (primary ab 1:200; Abcam Ab19898, Cambridge, UK) and sec-
ondary goat anti rabbit IgG Alexa 488 (1:250; Molecular Probes
A11008, OR, USA). Anti-inflammatory macrophages were visualized by
the double staining of CD68 and CD163 (1:400; Immunologic 1105-
C01, the Netherlands; secondary goat anti rabbit IgG Alexa 488 (1:250;
Molecular Probes A11008, OR, USA). Nuclei were visualized with
ProLong™ Gold Antifade Mountant with DAPI (Thermo Fisher P369,
MA, USA). Negative controls were obtained using an isotype antibody
and in addition for all stainings a positive control was taken along.
All slides were digitized using an automated microscopic scanner
(Panoramic digital MIDI, 3DHISTECH, Budapest, Hungary). For the
quantification of all immunofluorescence staining, the number of po-
sitive cells was counted in 8 random fields of view within the TC area at
60× (CD68+ and CD68+/GFP+) or 120× (SMA+/GFP+; SMA+/
GFP+/CD68+; CD68+/CD163+ and CD133+/GFP+/SMA+) magnifi-
cation, from which the mean was calculated. Quantification of bright
field Ki67 staining was performed with HistoQuant software (3DHIS-
TECH) by calculating % DAB positive area from the total tissue capsule
area.
2.7. Flow cytometry and blood and BM analysis
The peripheral blood was withdrawn from rat tail vein into tubes
containing 15% EDTA for FACS analysis. For the analysis of GFP+ cells
in the BM, complete BM was flushed out from femurs and tibia of rats
post-lethality. Red blood cell lysis buffer (1.2 mL, Sigma, St Louis, MO,
USA) was added into the tubes containing 0.1 mL blood and/or BM and
incubated at 37 °C for 5min followed by addition of 10mL PBS and
centrifugation to remove the lysed red blood cells. The cells (106 cells/
mL) were resuspended in 50mL FACS buffer (PBS containing 1% BSA
and 0.01% sodium azide) and incubated with Hoechst antibodies
(Thermo Fisher, MA, USA) for life/dead cell gating. GFP fluorescence
on the surface was determined by fluorescence-activated cell sorting
analysis (FACS, LSR II; BD Biosciences, CA, USA). Data were analyzed
using FACS-Diva software (BD Biosciences, CA, USA).
2.8. RNA isolation, cDNA synthesis and qPCR
Total RNA was extracted from VSMCs using Trizol reagent
(Invitrogen, CA, USA) according to the manufacturer's protocol. RNA
was reverse transcribed by M-MLV First-Strand Synthesis system
(Invitrogen, CA, USA), and used for quantitative analysis of rat genes
(Supplementary Table 1) with an SYBR Green Master Mix (Applied
Biosystems, CA, USA). Ribosomal protein S15 (RPS15) was used as
standard housekeeping gene. The relative mRNA expression levels were
determined using 2 [−ΔΔC(T)] method.
2.9. Statistical analysis
Results are expressed as mean ± SEM and considered statistically
significant for P < 0.05. T tests and Mann-Whitney tests for parametric
and nonparametric data, respectively, were used as appropriate.
3. Results
3.1. Surgical procedure
3.1.1. Generation of rats with GFP-labeled hematopoietic cells and chronic
kidney disease
To investigate the contribution of BM derived cells to TC formation,
we established a rat model where cells of the hematopoietic lineage
expressed GFP. SD rats were transplanted with BM cells derived from
transgenic GFP-SD rats. No immunological rejection occurred, as all of
the experimental animals underwent BM-transplantation survived and
demonstrated high engraftment of donor-derived GFP+ cells.
Percentage of GFP+ cells was evaluated by FACS analysis of the per-
ipheral blood at three time points: 1) 3 weeks after BM transplantation;
2) 6 weeks later, when the polymeric rods were implanted; and 3) when
the polymeric rods were excised from the TC, another 3 weeks later.
The percentages of GFP+ BMCs in the peripheral blood of the rats at
these 3 time points were 74 ± 1.6%; 80 ± 1.5%; and 77 ± 3%, re-
spectively. The percentage of GFP+ cells in the BM at time of TC har-
vest was 72 ± 3.6%.
Three weeks after BM transplantation, 17 rats underwent a 5/6
nephrectomy procedure from which 8 rats survived (47%). The healthy
control group (WT) comprised of 10 animals with BM transplant but
without the 5/6 nephrectomy procedure.
The CKD condition was established and persisted for the duration of
TC formation. At the time of TC harvest, histological analysis of the
remaining kidney of CKD rats revealed enlarged sclerotic glomeruli,
dilated tubuli, regions of tubular necrosis and cast formation
(Supplementary fig.1). These structural changes coincided with ele-
vated serum creatinine and BUN levels at the time of rod implantation
and rod extrusion (mean creatinine levels: implantation—WT 0.4mg/
dL, vs. CKD 0.94mg/dL, P= 0.0001; extrusion—WT 0.48mg/dL vs.
CKD 1.1mg/dL P= 0.0001; mean BUN levels: implantation—WT
15.2 mg/dL vs. CKD 31.1 mg/dL, P=0.0007; extrusion—WT 18.6mg/
dL vs. CKD 40.25mg/dL, P= 0.0005).
The high mortality rate (53%) of CKD animals was primarily due to
uremia as creatinine and blood urea nitrogen levels in these animals
were very high, emphasizing the severity of 5/6 nephrectomy model
(data not shown).
3.1.2. Implantation of the rods and TC harvest
Fabrication of implanted material was performed as previously de-
scribed [12]. To create a homogeneous porous surface along the rod, for
optimal inflammatory cell recruitment and organization of collagen and
myofibroblasts, rods were etched with chloroform. Chloroform etching
was verified using SEM (Supplementary fig.2).
Two weeks after induction of CKD, 4 polymer rods were implanted
into the subcutis of the rats in the abdominal area. TCs were harvested
at 1- and 3-weeks after subcutaneous implantation of the rods. The
study design is summarized in Fig. 1.
3.2. Tissue capsule formation
Cellular organization within the TC gradually changed from a dis-
organized, highly nucleated structure at 1-week, to circumferentially
aligned tissue at 3-weeks in both WT and CKD groups. TCs were mainly
composed of extracellular matrix components (Fig. 2a) and SMA+
myofibroblasts (Fig. 2b). The evolution of the TC formation was char-
acterized by an initial accumulation of CD68+ macrophages in proxi-
mity to the synthetic rod at the 1-week time point, whereas at 3-weeks
CD68+ cells were gradually dispersed through the entire TC volume
(Fig. 2c). Furthermore, the number of Ki67+ proliferating cells at 3-
weeks reduced by 40% and 67% (P=0.03) in WT and CKD animals,
respectively, when compared to the 1-week time point (Fig. 2d). The
collagen density gradually increased as the TC maturated, forming a
well-defined circular structure at 3-weeks in both WT and CKD animals
(Fig. 3a). Analysis of the total collagen content revealed increase in
total collagen amount in the TCs at 3 weeks in both WT and CKD ani-
mals (WT: 54% increase, P= 0.02; CKD: 61% increase, P= 0.01) when
compared to TCs obtained at 1 week after rod implantation (Fig. 3b).
No difference in collagen content was detected between WT and CKD
animals, indicating that CKD state has no major influence on collagen
synthesis in the TCs.
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3.3. A minority of inflammatory cells within TCs originates from the bone
marrow
The number of CD68+ macrophages in the TCs at 3-weeks increased
by 28% (P=0.03) and 82% (P= 0.0006) in WT and CKD animals
respectively, as compared to 1-week (Fig. 4a and b).
Analysis of CD68+/GFP+ cells within TC at 1-week revealed that
11.2 ± 1% and 16.9 ± 2% of CD68+ cells originated from the bone
marrow in WT and CKD group, respectively (Fig. 4a,c). The percentage
of BM-derived CD68+/GFP+ macrophages in TC at 3-weeks was
15.4 ± 2% and 11.3 ± 1.3% in WT and CKD group, respectively
(Fig. 4a,c). At 1-week time point, the percentage of CD68+ cells that
expressed GFP was 1.5 times higher in the CKD group as compared to
WT animals (P=0.03), whereas at 3-weeks this trend reversed
(Fig. 4c).
The percentage of CD68+/GFP+ cells, from the CKD group, de-
tected in the TC harvested at 3-weeks, was reduced by 33% as com-
pared to the 1-week time point (P= 0.02), (Fig. 4c).
3.4. Contribution of bone marrow derived cells to myofibroblasts population
in mature TCs
As described above, the TC harvested at 3-weeks was characterized
by an increase in SMA+ myofibroblasts and accumulation of collagen as
compared to TCs obtained at 1-week after rod implantation (Fig. 2b;
3a,b). Analysis of the TC harvested at 3-weeks revealed that 36% and
35% of SMA+ cells were originating from the BM as they were positive
for GFP in WT and CKD group, respectively (Fig. 5a and b). Moreover,
29% and 23% of SMA+/GFP+ myofibroblasts co-expressed a macro-
phage marker CD68 in the WT and CKD group, respectively (Fig. 5a,c),
Fig. 1. Schematic representation of the project work flow. (1) 2*107 of total bone marrow cells harvested from transgenic Sprague Dawley (SD) rats ubiquitously
expressing green fluorescent protein (GFP) were injected into the tail vein of wild-type (WT) SD recipient rats; n= 27. Three weeks after the bone marrow
reconstitution percentage of GFP+ cells in the peripheral blood of recipient rats was measured by FACS analysis. (2) 2-step induction of chronic kidney disease (CKD);
1) unilateral right side nephrectomy and 2) 2/3 subtotal nephrectomy of the left kidney. Degree of CKD was confirmed by serum creatinine and blood urea nitrogen
(BUN) levels 2 weeks after the procedure. (3) Polymeric rods were implanted into subcutaneous space of CKD and WT animals. (4) After 1 and 3 weeks implantation,
rods together with formed fibrocellular tissue capsule were extruded and processed for further analysis. n= 10 WT, n= 8 CKD group. (For interpretation of the
references to color in this figure legend, the reader is referred to the Web version of this article.)
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suggesting a role for macrophage to myofibroblasts transition in TC
formation.
3.5. Tissue-resident macrophages in TC formation
There is accumulating evidence that tissue-resident macrophages
orchestrate tissue-repair responses [23]. Immunohistochemical analysis
of the TCs obtained at 3 weeks after rod implantation revealed that 53%
and 58% of CD68+ macrophages expressed the anti-inflammatory
marker CD163+, in WT and CKD animals respectively (Fig. 6a and b).
Gene expression analysis confirmed the repair-associated phenotype of
these cells, as mRNA levels of transforming growth factor beta (TGFβ)
in WT group was elevated by 2-fold (P=0.03), whereas mRNA levels
of the anti-inflammatory cytokine IL10 in CKD group was 2-fold higher
(P= 0.04) in the TCs harvested at 3-weeks as compared to 1-week time
point (Fig. 6b).
3.6. Discrete population of cells positive for stem/progenitor-cell marker
CD133
We observed a population of GFP+/CD68- cells that accumulated
predominantly at the outside border of the TC (Supplementary fig.3).
Interestingly, nearly all of these GFP+/CD68- cells expressed CD133, a
marker of progenitor cells of various origin [24], in both WT and CKD
animals. Moreover, 24% of the CD133+/GFP+ cells co-expressed SMA
(Fig. 7a and b) indicating that BM derived hematopoietic stem cells can
serve as direct precursors to myofibroblasts in mature TCs.
4. Discussion
In the present study, we showed that both BM-derived and tissue-
resident cells contribute to TC formation upon subcutaneous polymeric
rod implantation. Surprisingly, only 13% of the macrophages within the
TC originated from the BM, whereas 36% of the myofibroblast
originated from BM precursors. A substantial number of SMA+ bone
marrow derived myofibroblasts co-expressed CD68, highlighting the
role of the macrophage-to-myofibroblast transition in the formation of
the TC. During the maturation of the TC, the cellular response pre-
dominantly displayed repair associated characteristics. Importantly, the
CKD condition did not significantly affect the process of TC formation.
4.1. Tissue-resident and BM-derived cells both contribute to the
inflammatory response upon polymer rod implantation
Several studies have shown that the encapsulation of the foreign
body is initiated with an inflammatory response, mainly through the
activity of macrophages [14,15,25–27]. In this study, we also observed
that along the inner border – adjacent to the polymeric rod – the tissue
capsules were mainly composed of CD68+ macrophages. Remarkably,
only a minority of the macrophages within the TC originated from the
bone marrow, as only 13% of the total CD68+ population co-expressed
GFP. Several studies suggest that cells within the local tissue environ-
ment, such as tissue-resident macrophages, also contribute to the for-
eign body response and play major role in the formation of engineered
tissue [28–30]. Tissue-resident macrophages consist of a mixture of
embryonic- and adult-hematopoietic stem cell-derived macrophages,
which have the capacity to self-renewal throughout adulthood [31,32].
Here, we show that the maturation of the TC is associated with a
40% increase in tissue-resident CD68+/CD163+ macrophages along
with increase in IL10 and pro-fibrotic TGFβ mRNA levels within TCs.
Besides, we did not observe a significant difference in CD68+/CD163+
macrophage population between CKD (46% of total macrophages) and
WT animals (38%). Myofibroblast content was also similar between the
groups. The latter most likely explains the similarity in collagen content
in TCs as collagen is predominantly synthesized by (myo)fibroblasts.
Fig. 2. Cellular composition of tissue capsule at 1 and 3 weeks post-implantation. Immunohistochemical staining of (a) various constituents of connective
tissues by MOVAT; (b) SMA+ myofibroblasts, (c) CD68+ macrophages and (d) Ki67+ proliferating cells in the TC from healthy controls (WT) and chronic kidney
disease (CKD) rats harvested at 1 and 3 weeks post-implantation. n= 10 WT, n= 8 CKD group.
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4.2. Macrophages as precursors of myofibroblasts
During the development of the TC, we observed a gradual transition
from granulation tissue towards circumferentially aligned SMA+ myo-
fibroblasts, whereas a substantial proportion of the myofibroblasts in
the TCs were derived from hematopoietic BMCs. The ability of BM-
derived cells to differentiate into smooth muscle-like cells was first
described by Campbell and coworkers in their experimental work on TC
formation in the peritoneal cavity [33]. Subsequent studies from the
same group confirmed the plasticity of peritoneal macrophages and
their ability to transdifferentiate from a myeloid to mesenchymal
phenotype [34]. In our model, 26% of myofibroblasts originated from
BM-derived macrophages, which illustrates the importance of macro-
phage-to-myofibroblast transition during the TC development.
4.3. Contribution of bone marrow progenitor cells to TC formation
Possibly, other than BM-derived and/or tissue resident macrophages
can contribute to TC formation. A recent study by Wang et al. showed
that Sox10+ adult mouse stem cells found within the stroma of sub-
cutaneous loose connective tissues, can contribute to encapsulation,
fibrosis, and microvascularization of biomaterials upon implantation
[35]. Interestingly, we observed a population of CD133+/GFP+ cells at
the outer border of the TCs. Previous studies revealed that the mem-
brane bound glycoprotein CD133 is expressed in mesenchymal stem
cells (MSCs) [36] and stromal cells [37] within the BM. Both MSCs and
stromal cells can give rise to human osteoblasts, adipocytes, chon-
drocytes as well as fibroblasts [38,39]. In this study, 24% CD133+/
GFP+ cells were positive for SMA+ suggesting that CD133+ BM-de-
rived cells can contribute to the myofibroblast population in mature
Fig. 3. Changes in collagen content over the time course of tissue capsule maturation. (a) Picrosirius red staining of the collagen. The collagen density
gradually increased forming a well-defined circular structure at 3 weeks in both WT and CKD animals. (b) Analysis of the total collagen amount measured by
QuickZyme Total Collagen Assay Kit. Significant increase in collagen content within WT and CKD groups was observed. (*) P < 0.05; n = 10 WT, n = 8 CKD group.
(For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
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tissue capsules.
4.4. CKD does not influence the cellular response during TC formation
As discussed above, the process of TC formation involves an acute
inflammatory response, followed by chronic inflammation and fibrosis
culminating in the encapsulation of the implanted biomaterial. CKD is a
pro-fibrotic condition associated with tissue scarring as well as kidney
and cardiac fibrosis [40–42]. Excessive TGFβ signaling, which has been
implicated in epithelial cells and fibroblasts in CKD [41], can
potentially enhance the process of TC formation in the subcutaneous
space. On the other hand, CKD is associated with impaired function of
both the innate and adaptive immune systems [17]. Circulating CD34+
progenitor cells are markedly reduced in patients with CKD. In addi-
tion, monocyte-macrophages are more prone to apoptosis in CKD pa-
tients,[43], which could also negatively influence TC formation in CKD
patients.
In the present study, we did not observe a significant effect of CKD
on the cellular response upon implantation of the polymer rod. We
hypothesize that the local foreign body response upon implantation of
Fig. 4. Macrophages in tissue capsule formation. (a) Immunofluorescence staining of CD68+ macrophage marker (red color) and bone marrow derived GFP
marker (light blue color). CD68+/GFP+ bone marrow derived macrophages (white arrows) was detected in the TC harvested at 1 and 3 weeks in WT and CKD group.
(b) Quantification of total CD68+ macrophages within TC harvested at 1 and 3 weeks in WT and CKD animals. (c) Quantification of CD68+/GFP+ bone marrow
derived macrophages from total CD68+ population. Nuclei DAPI (blue color). (*) P < 0.05; (***) P < 0.001; n = 10 WT, n = 8 CKD group. (For interpretation of
the references to color in this figure legend, the reader is referred to the Web version of this article.)
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the polymer rod substantially differs from chronic inflammation and
subsequent tissue fibrosis as observed in various organs of patients with
CKD.
After only 3 weeks, tissue capsules were well matured, indicating
the importance of the acute response and that the local environment
within subcutaneous space is sufficient to maintain the process of TC
formation.
Some aspects of our study require further discussion. One limitation
in particular is the imperfect efficacy of the bone marrow transplanta-
tion, as only 75–80% of the cells in the peripheral blood were GFP+
after BM-transplantation. As a consequence, the contribution of bone
marrow derived cells in TC formation might be underestimated.
Our technology of tissue engineered blood vessels is aimed for pa-
tients with stage 5 of CKD which is defined as ESRD, when renal re-
placement therapy is required to survive. It is important to emphasize
that the 5/6-nephrectomy model used in the current study does not
fully resemble ESRD, as the glomerular filtration rate (GFR) in this
model is around 29-15% of normal (CKD stage 4). Therefore, caution is
required when extrapolating these results to humans as TC formation in
these rats might be different when compared to dialysis patients.
Furthermore, the pathophysiological mechanisms underlying CKD are
also different between 5/6 nephrectomy animals and patients with
CKD. Nevertheless, the 5/6-nephrectomy model in rats remains the
most valuable and extensively investigated animal model mimicking
human CKD [44–47].
Another limitation of this study is the inability to measure the
mechanical strength of the TCs, an important parameter defining TC
suitability for vascular grafting. However, a recent study performed in
pigs demonstrates that the burst pressure and suture retention strength
of the autologous TCs are sufficient to allow safe implantation in the
arterial circulation [13].
5. Conclusion
This study illustrates that both BM-derived and resident cells con-
tribute to the process of tissue response directed to a polymer rod that
culminates in the formation of a collagen rich fibrocellular tissue cap-
sule. BM-derived- as well as tissue resident macrophages serve as pre-
cursors of myofibroblasts in matured TCs. Notably, the presence of CKD
does not significantly alter the process of TC formation, which supports
the suitability of our autologous vascular tissue engineering approach
for future clinical use in CKD patients.
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